

Paul Nghiem

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8514621/paul-nghiem-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212
papers

13,070
citations

63
h-index

111
g-index

288
ext. papers

15,697
ext. citations

6.4
avg, IF

6.26
L-index

#	Paper	IF	Citations
212	Recurrence and Mortality Risk of Merkel Cell Carcinoma by Cancer Stage and Time From Diagnosis.. <i>JAMA Dermatology</i> , 2022 ,	5.1	1
211	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. <i>Science Translational Medicine</i> , 2021 , 13, eaba6006	17.5	3
210	Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. <i>Journal of Dermatological Science</i> , 2021 ,	4.3	1
209	Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. <i>ESMO Open</i> , 2021 , 6, 100290	6	8
208	New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy.. <i>Patterns</i> , 2021 , 2, 100372	5.1	4
207	Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma 2021 , 9,		10
206	How we treat Merkel cell carcinoma: within and beyond current guidelines. <i>Future Oncology</i> , 2021 , 17, 1363-1377	3.6	4
205	In Regard to Barker. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100685	3.3	
204	Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9517-9527	22.3	4
203	A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS9592-TPS9592	2.2	1
202	Spatial transcriptomics at subspot resolution with BayesSpace. <i>Nature Biotechnology</i> , 2021 , 39, 1375-1384	44.5	47
201	Response to "Mohs surgery for early-stage Merkel cell carcinoma (MCC) achieves local control better than wide local excision +/- radiation therapy with no increase in MCC-specific death". <i>International Journal of Dermatology</i> , 2021 ,	1.7	
200	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021 , 13,	6.6	3
199	First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study 2021 , 9,		9
198	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2021 , 184, 319-327	4	12
197	Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 340-347	4.5	10
196	Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 330-339	4.5	11

195	Lack of efficacy of radiation therapy plus PD-L1 blockade for Merkel cell carcinoma arising in a patient with chronic active Epstein-Barr virus infection. <i>Dermatologic Therapy</i> , 2021 , 34, e14722	2.2	0
194	Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients. <i>JAAD Case Reports</i> , 2021 , 8, 28-33	1.4	1
193	Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1897-1905	4.3	2
192	Merkel cell carcinoma can be indolent: A case with 7 locoregional recurrences over 15 years highlights the importance of patient-tailored management. <i>JAAD Case Reports</i> , 2021 , 16, 58-61	1.4	
191	Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial 2020 , 8,		70
190	Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 295-296	4.5	11
189	Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. <i>Molecular Carcinogenesis</i> , 2020 , 59, 807-821	5	19
188	Immune checkpoint inhibitors to treat cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1239-1253	4.5	30
187	The 6-4 photoproduct is the trigger of UV-induced replication blockage and ATR activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 12806-12816	11.5	6
186	Patterns of distant metastases in 215 Merkel cell carcinoma patients: Implications for prognosis and surveillance. <i>Cancer Medicine</i> , 2020 , 9, 1374-1382	4.8	21
185	Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1667-1677	12.9	11
184	PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy 2020 , 8,		12
183	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2020 , 4, 3239-3245	7.8	6
182	Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020 , 16, 2089-2099	3.6	1
181	Efficacy and Toxicity of Hypofractionated Adjuvant Radiotherapy in Merkel Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, E46	4	2
180	Postoperative, Single-Fraction Radiation Therapy in Merkel Cell Carcinoma of the Head and Neck. <i>Advances in Radiation Oncology</i> , 2020 , 5, 1248-1254	3.3	8
179	Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020 , 26, 598-607	12.9	34
178	Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2476-2487	2.2	72

177	Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8 T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. <i>Cancer Immunology Research</i> , 2020 , 8, 648-659	12.5	9
176	Less Toxic, More Effective Treatment-A Win-Win for Patients With Merkel Cell Carcinoma. <i>JAMA Dermatology</i> , 2019 , 155, 1223-1224	5.1	7
175	One in a hundred million: Merkel cell carcinoma in pediatric and young adult patients is rare but more likely to present at advanced stages based on US registry data. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 1758-1760	4.5	2
174	Travel burden associated with rare cancers: The example of Merkel cell carcinoma. <i>Cancer Medicine</i> , 2019 , 8, 2580-2586	4.8	13
173	Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 693-702	2.2	188
172	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 609-618	7.4	18
171	Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 1185-1195	12.9	59
170	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 733-740	3.4	5
169	Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know. <i>Radiographics</i> , 2019 , 39, 2069-2084	3.4	9
168	Tuberculosis following PD-1 blockade for cancer immunotherapy. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	99
167	Human CD4 T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain. <i>Cancer Immunology Research</i> , 2019 , 7, 1727-1739	12.5	12
166	Differential Outcomes Among Immunosuppressed Patients With Merkel Cell Carcinoma: Impact of Immunosuppression Type on Cancer-specific and Overall Survival. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 82-88	2.7	21
165	Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. <i>Clinical Cancer Research</i> , 2018 , 24, 3644-3655	12.9	11
164	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 457-463.e2	4.5	211
163	Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival. <i>Clinical Cancer Research</i> , 2018 , 24, 963-971	12.9	34
162	The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: An international assessment. <i>European Journal of Cancer</i> , 2018 , 94, 47-60	7.5	53
161	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5873-5882	12.9	35
160	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after 1-year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial 2018 , 6, 7		191

159	Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 742-774	7.3	134
158	Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9505-9505	2.2	27
157	Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9506-9506	2.2	13
156	Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9507-9507	2.2	27
155	ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS9605-TPS9605	2.2	4
154	18-month efficacy and safety update from JAVELIN Merkel 200 part A: A phase II study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 192-192	2.2	9
153	Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. <i>American Journal of Case Reports</i> , 2018 , 19, 505-511	1.3	16
152	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. <i>International Journal of Particle Therapy</i> , 2018 , 5, 183-195	1.5	9
151	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEK. <i>Cancer Immunology, Immunotherapy</i> , 2018 , 67, 341-351	7.4	54
150	Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018 , 24, 2035-2043	12.9	51
149	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes. <i>Nature Biotechnology</i> , 2018 ,	44.5	57
148	Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy 2018 , 6, 131		29
147	The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 763-776	19.4	125
146	Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab 2018 , 6, 99		73
145	Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. <i>Nature Communications</i> , 2018 , 9, 3868	17.4	123
144	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report 2018 , 6, 82		21
143	Effect of Patient Immune Status on the Efficacy of Radiation Therapy and Recurrence-Free Survival Among 805 Patients With Merkel Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 330-339	4	20
142	Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. <i>Cancer Immunology Research</i> , 2017 , 5, 137-147	12.5	51

141	Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 281-287	3.5	7
140	Polyomavirus-Negative Merkel Cell Carcinoma: A More Aggressive Subtype Based on Analysis of 282 Cases Using Multimodal Tumor Virus Detection. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 819-827	4.3	136
139	Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. <i>Scientific Reports</i> , 2017 , 7, 2290	4.9	62
138	DGCR8 Mediates Repair of UV-Induced DNA Damage Independently of RNA Processing. <i>Cell Reports</i> , 2017 , 19, 162-174	10.6	20
137	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017 , 13, 1263-1279	3.6	77
136	Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. <i>Cancer</i> , 2017 , 123, 1464-1474	6.4	88
135	Merkel cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17077	51.1	219
134	CD200 Expression in Neuroendocrine Neoplasms. <i>American Journal of Clinical Pathology</i> , 2017 , 148, 236-242	4.2	19
133	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolimmunology</i> , 2017 , 6, e1338237	7.2	36
132	Abstract 662: The differential association of PD-1, PD-L1, and CD8+ cells with response to pembrolizumab and presence of Merkel cell polyomavirus (MCPyV) in patients with Merkel cell carcinoma (MCC) 2017 ,		6
131	Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) 2017 ,		81
130	Abstract CT079: Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year efficacy update 2017 ,		17
129	Augmentation of adoptive T-cell therapy for Merkel cell carcinoma with avelumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3044-3044	2.2	6
128	Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9557-9557	2.2	3
127	Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 80-80	2.2	2
126	Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma. <i>International Journal of Particle Therapy</i> , 2017 , 3, 485-491	1.5	4
125	Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	114
124	Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy: Results of the phase 2 JAVELIN Merkel 200 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9508-9508	2.2	6

123	Systematic literature review of efficacy, safety, and tolerability outcomes of interventions in patients with distant metastatic Merkel cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21018-e21018		
122	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. <i>Oncotarget</i> , 2016 , 7, 3403-15	3.3	229
121	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016 , 12, 649-50	3.1	5
120	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016 , 8, 907-21	3.8	16
119	Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 574-97	7.3	123
118	Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. <i>Scientific Reports</i> , 2016 , 6, 21678	4.9	31
117	Postoperative radiation therapy is associated with a reduced risk of local recurrence among low risk Merkel cell carcinomas of the head and neck. <i>Advances in Radiation Oncology</i> , 2016 , 1, 244-251	3.3	26
116	Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3564-3571	3.1	261
115	Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 541-547	4.5	13
114	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016 , 374, 2542-52	59.2	828
113	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1374-1385	21.7	818
112	Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2016 , 5, 2294-301	4.8	156
111	How does the Merkel polyomavirus lead to a lethal cancer? Many answers, many questions, and a new mouse model. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1221-1224	4.3	12
110	22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma. <i>European Journal of Cancer</i> , 2015 , 51, S720-S721	7.5	15
109	504 Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study. <i>European Journal of Cancer</i> , 2015 , 51, S104	7.5	10
108	Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma. <i>Cancer Medicine</i> , 2015 , 4, 1161-70	4.8	45
107	Merkel Cell Carcinoma: Intersection of Immune Dysfunction, Infection, and Malignant Progression. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2015 , 17, 36	1.1	2
106	Why Do Airline Pilots and Flight Crews Have an Increased Incidence of Melanoma?. <i>JAMA Oncology</i> , 2015 , 1, 829-30	13.4	7

105	Pilot study of intratumoral G100, toll-like receptor-4 (TLR4) agonist, therapy in patients with Merkel cell carcinoma (MCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3083-3083	2.2	1
104	Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. <i>Cancer Immunology Research</i> , 2014 , 2, 1071-9	12.5	90
103	Pathogen-driven cancers and emerging immune therapeutic strategies. <i>Cancer Immunology Research</i> , 2014 , 2, 9-14	12.5	30
102	Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 637-643	4.5	92
101	Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 449-55	4.5	14
100	Dermatofibrosarcoma protuberans, version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 863-8	7.3	24
99	Milestones in the staging, classification, and biology of Merkel cell carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 1255-62	7.3	23
98	Merkel cell carcinoma, version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 410-24	7.3	35
97	CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 452-8	1.9	71
96	Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity. <i>Cancer Research</i> , 2014 , 74, 7534-45	10.1	17
95	Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. <i>Cancer Immunology Research</i> , 2014 , 2, 27-36	12.5	69
94	Effect of host, tumor, diagnostic, and treatment variables on outcomes in a large cohort with Merkel cell carcinoma. <i>JAMA Dermatology</i> , 2014 , 150, 716-23	5.1	62
93	T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. <i>Clinical Cancer Research</i> , 2014 , 20, 1768-78	12.9	66
92	A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3007-3007	2.2	36
91	Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: Survival analysis of 6,908 cases from the National Cancer Data Base.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9014-9014	2.2	4
90	Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9091-9091	2.2	10
89	Pathologic nodal evaluation is increasingly commonly performed for patients with Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 653-4	4.5	18
88	Track and Attack: Emerging Prognostic and Therapeutic Approaches 2013 , 171-184		

87	Case Study C: Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver 2013 , 161-163		
86	Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1879-89	4.3	74
85	Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. <i>Current Treatment Options in Oncology</i> , 2013 , 14, 249-63	5.4	48
84	Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers 2013 , 1, P13		78
83	Vascular E-selectin expression correlates with CD8 lymphocyte infiltration and improved outcome in Merkel cell carcinoma. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2065-73	4.3	39
82	Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 642-646	4.3	148
81	p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. <i>American Journal of Clinical Pathology</i> , 2013 , 140, 838-44	1.9	39
80	Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. <i>Clinical Cancer Research</i> , 2013 , 19, 5351-60	12.9	143
79	Mechanisms of Caffeine-Induced Inhibition of UVB Carcinogenesis. <i>Frontiers in Oncology</i> , 2013 , 3, 144	5.3	26
78	Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. <i>Journal of Virology</i> , 2013 , 87, 6118-26	6.6	82
77	Inhibition of UVB-induced nonmelanoma skin cancer: a path from tea to caffeine to exercise to decreased tissue fat. <i>Topics in Current Chemistry</i> , 2013 , 329, 61-72		9
76	The Safety and Efficacy of Primary Radiation Therapy Without Upfront Surgery for Merkel Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, S168	4	2
75	Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role?. <i>Global Advances in Health and Medicine</i> , 2012 , 1, 22-3	1.9	8
74	Surgical removal of the parametrial fat pads stimulates apoptosis and inhibits UVB-induced carcinogenesis in mice fed a high-fat diet. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9065-70	11.5	21
73	Importance of genetic studies in patients with multiple merkel cell carcinomas. <i>Acta Dermato-Venereologica</i> , 2012 , 92, 633; author reply p.634	2.2	1
72	Dermatofibrosarcoma protuberans. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012 , 10, 312-8	7.3	27
71	Abstract LB-430: Anti-polyomavirus CTL targeting Merkel cell carcinoma combined with MHC class I upregulation induces tumor regression 2012 ,		2
70	Diagnostic biopsy does not commonly induce intratumoral CD8 T cell infiltration in Merkel cell carcinoma. <i>PLoS ONE</i> , 2012 , 7, e41465	3.7	9

69	Identification and validation of a novel mature microRNA encoded by the Merkel cell polyomavirus in human Merkel cell carcinomas. <i>Journal of Clinical Virology</i> , 2011 , 52, 272-5	14.5	67
68	Asymmetric lateral distribution of melanoma and Merkel cell carcinoma in the United States. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 35-9	4.5	38
67	A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. <i>Journal of the American Academy of Dermatology</i> , 2011 , 64, 1051-9	4.5	183
66	Left-sided skin cancers on the arm from driving? Past and future lessons from Australia. <i>Journal of the American Academy of Dermatology</i> , 2011 , 65, 1229	4.5	2
65	Merkel cell carcinoma associated with HIV: review of 14 patients. <i>Aids</i> , 2011 , 25, 119-21	3.5	25
64	Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. <i>Current Oncology Reports</i> , 2011 , 13, 488-97	6.3	78
63	Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1539-46	2.2	226
62	Caffeine decreases phospho-Chk1 (Ser317) and increases mitotic cells with cyclin B1 and caspase 3 in tumors from UVB-treated mice. <i>Cancer Prevention Research</i> , 2011 , 4, 1118-25	3.2	24
61	Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. <i>Clinical Cancer Research</i> , 2011 , 17, 6671-80	12.9	105
60	Chemical methodology as a source of small-molecule checkpoint inhibitors and heat shock protein 70 (Hsp70) modulators. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 6757-62	11.5	54
59	Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 13716-21	11.5	42
58	Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. <i>Cancer Research</i> , 2010 , 70, 8388-97	10.1	173
57	Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. <i>Journal of the American Academy of Dermatology</i> , 2010 , 63, 751-61	4.5	409
56	Basal cell and squamous cell skin cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 836-64	7.3	76
55	Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma. <i>Cancer</i> , 2010 , 116, 1783-90	6.4	119
54	Clinical recognition, diagnosis, and staging of merkel cell carcinoma, and the role of the multidisciplinary management team. <i>Current Problems in Cancer</i> , 2010 , 34, 38-46	2.3	18
53	Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin. <i>Archives of Pathology and Laboratory Medicine</i> , 2010 , 134, 341-4	5	26
52	Carcinogenesis: UV Radiation* 2010 , 567-578		1

51	Current Staging Systems for Merkel Cell Carcinoma. <i>Molecular Medicine and Molecular</i> , 2010 , 131-141		
50	Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1510-22	9.7	193
49	Merkel cell polyomavirus is more frequently present in North American than Australian Merkel cell carcinoma tumors. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 246-8	4.3	232
48	Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1547-55	4.3	95
47	ATR-Chk1 pathway inhibition promotes apoptosis after UV treatment in primary human keratinocytes: potential basis for the UV protective effects of caffeine. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 1805-15	4.3	63
46	Toward better management of merkel cell carcinoma using a consensus staging system, new diagnostic codes and a recently discovered virus. <i>Actas Dermo-sifilograficas</i> , 2009 , 100 Suppl 2, 49-54	0.5	12
45	Merkel cell polyomavirus is not detected in prostate cancers, surrounding stroma, or benign prostate controls. <i>Journal of Clinical Virology</i> , 2009 , 44, 164-6	14.5	18
44	Merkel cell carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009 , 7, 322-32	7.3	46
43	Does a new polyomavirus contribute to Merkel cell carcinoma?. <i>Genome Biology</i> , 2008 , 9, 228	18.3	16
42	Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. <i>Journal of the American Academy of Dermatology</i> , 2008 , 58, 375-81	4.5	611
41	Effect of caffeine on the ATR/Chk1 pathway in the epidermis of UVB-irradiated mice. <i>Cancer Research</i> , 2008 , 68, 2523-9	10.1	55
40	Case 19-2008: Merkel-cell carcinoma. <i>New England Journal of Medicine</i> , 2008 , 359, 1629-30; author reply 1630-1	59.2	
39	Merkel cell carcinoma: if no breslow, then what?. <i>Journal of Surgical Oncology</i> , 2007 , 95, 614-5	2.8	4
38	Chemical genetics: elucidating biological systems with small-molecule compounds. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1577-84	4.3	63
37	Merkel cell carcinoma: more deaths but still no pathway to blame. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 2100-3	4.3	156
36	Protection from photodamage by topical application of caffeine after ultraviolet irradiation. <i>British Journal of Dermatology</i> , 2007 , 156, 957-64	4	41
35	The protective role of a small GTPase RhoE against UVB-induced DNA damage in keratinocytes. <i>Journal of Biological Chemistry</i> , 2007 , 282, 4850-4858	5.4	30
34	Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy. <i>Journal of the American Academy of Dermatology</i> , 2007 , 57, 166-9	4.5	122

33	Basal cell and squamous cell skin cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 506-29	7.3	20
32	Dermatofibrosarcoma protuberans. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, 550-5	7.3	5
31	Role of skin biopsy to confirm suspected acute graft-vs-host disease: results of decision analysis. <i>Archives of Dermatology</i> , 2006 , 142, 175-82		49
30	Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature. <i>Archives of Dermatology</i> , 2006 , 142, 685-90		265
29	A robust small-molecule microarray platform for screening cell lysates. <i>Chemistry and Biology</i> , 2006 , 13, 493-504		114
28	Merkel cell carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006 , 4, 704-12	7.3	13
27	Protein Kinases as Targets in Cancer Therapy: Validated and Emerging Approaches 2005 , 291-315		
26	Human immunodeficiency virus type 1 Vpr-mediated G2 arrest requires Rad17 and Hus1 and induces nuclear BRCA1 and gamma-H2AX focus formation. <i>Molecular and Cellular Biology</i> , 2004 , 24, 9286-94	4.8	111
25	Interactive Atlas of Dermoscopy. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 807-808	4.5	12
24	Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2004 , 51, 543-6	4.5	71
23	Identification and Characterization of Novel Small-Molecule Inhibitors of the Replication Checkpoint.. <i>Blood</i> , 2004 , 104, 763-763		2.2
22	Integration of growth factor and nutrient signaling: implications for cancer biology. <i>Molecular Cell</i> , 2003 , 12, 271-80	17.6	172
21	Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. <i>Journal of Biological Chemistry</i> , 2003 , 278, 25879-86	5.4	158
20	Merkel cell carcinoma treatment with radiation: a good case despite no prospective studies. <i>Archives of Dermatology</i> , 2003 , 139, 1641-3		7
19	ATR is not required for p53 activation but synergizes with p53 in the replication checkpoint. <i>Journal of Biological Chemistry</i> , 2002 , 277, 4428-34	5.4	84
18	ATR regulates fragile site stability. <i>Cell</i> , 2002 , 111, 779-89	56.2	465
17	The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 640-2	4.5	30
16	Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2002 , 46, 228-41	4.5	189

15	Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. <i>Archives of Dermatology</i> , 2001 , 137, 1202-6		69
14	The "drug vs graft-vs-host disease" conundrum gets tougher, but there is an answer: the challenge to dermatologists. <i>Archives of Dermatology</i> , 2001 , 137, 75-6		19
13	"Topical immunomodulators?": introducing old friends and a new ally, tacrolimus. <i>Journal of the American Academy of Dermatology</i> , 2001 , 44, 111-3	4.5	8
12	ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 9092-7	11.5	265
11	Identifying the missing link between UV and p53: the role of phosphatidyl inositol kinase-related kinases. <i>Journal of the American Academy of Dermatology</i> , 2000 , 43, 706-7	4.5	1
10	Basal- and Squamous-Cell Carcinomas 1998 , 785-788		
9	Localization of the CAMKG gene encoding gamma isoforms of multifunctional calcium/calmodulin-dependent protein kinase (CaM kinase) to human chromosome 10 band q22 and mouse chromosome 14. <i>Cytogenetic and Genome Research</i> , 1994 , 66, 113-6	1.9	8
8	Interleukin-2 transcriptional block by multifunctional Ca ²⁺ /calmodulin kinase. <i>Nature</i> , 1994 , 371, 347-50	5.4	102
7	Cloning and analysis of two new isoforms of multifunctional Ca ²⁺ /calmodulin-dependent protein kinase. Expression in multiple human tissues. <i>Journal of Biological Chemistry</i> , 1993 , 268, 5471-9	5.4	80
6	Cloning and analysis of two new isoforms of multifunctional Ca ²⁺ /calmodulin-dependent protein kinase. Expression in multiple human tissues.. <i>Journal of Biological Chemistry</i> , 1993 , 268, 5471-5479	5.4	72
5	Antisense oligodeoxynucleotides to the cystic fibrosis transmembrane conductance regulator inhibit cAMP-activated but not calcium-activated chloride currents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 6785-9	11.5	63
4	Prostaglandin E1 activates a chloride current in Jurkat T lymphocytes via cAMP-dependent protein kinase. <i>FASEB Journal</i> , 1991 , 5, 2965-70	0.9	8
3	Merkel Cell Carcinoma in Organ Transplant Recipients 190-194		
2	857 LAMP1 targeting of the large T antigen of merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth		1
1	New interpretable machine learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy		6